Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - (tablet core, product) drospirenone; (tablet core, product) ethinylestradiol betadex clathrate - tablet, film coated - 3.000 mg - (tablet core, product) drospirenone 3.000 mg; (tablet core, product) ethinylestradiol betadex clathrate 0.020 mg

Singapore - English - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - (tablet core) budesonide micronized - tablet, film coated, extended release - (tablet core) budesonide micronized 9.0 mg

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

new medical centre trading united arab emirates - 30 tablets (3 x 10's blister) - tablet - 10mg/tablet - nervous system-n/a

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pravastatin sodium, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose; sodium stearylfumarate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. cholvastin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. cholvastin is indicated in patients with unstable angina pectoris see clinical trials). 4. cholvastin is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials). 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. vastoran is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. vastoran is indicated in patients with unstable angina pectoris see clinical trials). 4. vastoran is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pravastatin sodium, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose; sodium stearylfumarate; iron oxide yellow - 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. cholvastin is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. cholvastin is indicated in patients with unstable angina pectoris see clinical trials). 4. cholvastin is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials). 1. as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (eg; poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. 2. vastoran is indicated in patients with previous myocardial infarction including those who have normal (4.0 - 5.5 mmol/l) serum cholesterol levels. 3. vastoran is indicated in patients with unstable angina pectoris see clinical trials). 4. vastoran is also indicated as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years of age or older (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; magnesium carbonate hydrate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: calcium sulfate dihydrate; magnesium stearate; magnesium carbonate hydrate; colloidal anhydrous silica; crospovidone; povidone; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; magnesium carbonate hydrate; calcium sulfate dihydrate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; xanthan gum; iron oxide yellow; purified talc; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 25 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: magnesium stearate; polysorbate 80; hypromellose; colloidal anhydrous silica; mannitol; sodium starch glycollate type b; povidone; titanium dioxide; iron oxide red; macrogol 3350; carnauba wax; iron oxide black - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydrochlorothiazide, quantity: 12.5 mg; irbesartan, quantity: 300 mg - tablet, film coated - excipient ingredients: povidone; polysorbate 80; sodium starch glycollate type b; hypromellose; colloidal anhydrous silica; magnesium stearate; mannitol; iron oxide red; iron oxide yellow; titanium dioxide; carnauba wax; macrogol 3350 - indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.